Scholarlink

Background and Objective <p>The investigational DNA-damage response inhibitor tuvusertib showed the formation of a direct glucuronide in hepatocyte incubations. Early metabolite identification workflows were unable to assign the site of modification. Thus, a synthesis approach was established to facilitate structure elucidation as well as an initial characterization regarding drug–drug interaction and safety.</p> Methods <p>Different methods for generating sufficient amounts of the glucuronide were assessed and after purification structure elucidation of the glucuronide was performed via nuclear magnetic resonance spectroscopy (NMR). A series of in vitro experiments were conducted to determine its potential risk for drug–drug interaction. Confirmation of its identity was achieved by co-chromatography with hepatic incubations, which initially showed the presence of the metabolite.</p> Results <p>Chemical synthesis showed the most promising route for the formation of the proposed glucuronide and NMR determined the modification to be at the primary amino group attached to the pyrazolo-pyrimidine moiety. The retention time as well as the mass spectra in the co-chromatography aligned with the glucuronide of interest in the hepatocyte incubation, confirming the synthesized metabolite to be M1. Subsequent in vitro experiments showed that M1 did not inhibit any major CYP enzyme.</p> Conclusions <p>The tuvusertib metabolite M1 was identified as an <i>N</i>-glucuronide demonstrating no direct liabilities associated with drug–drug interactions (DDI) or safety implications. Furthermore, M1 can be used in bioanalyses as retention time marker or reference material in further clinical evaluations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structure Elucidation and Initial Characterization of a N-glucuronide Metabolite (M1) of Tuvusertib

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月16日

查看全文
  • Benedikt Lang,
  • Hanno Schieferstein,
  • Kai Thede,
  • Matthias Bader,
  • Tianjing Ren,
  • Jatinder Kaur Mukker,
  • Holger Scheible

摘要

Background and Objective

The investigational DNA-damage response inhibitor tuvusertib showed the formation of a direct glucuronide in hepatocyte incubations. Early metabolite identification workflows were unable to assign the site of modification. Thus, a synthesis approach was established to facilitate structure elucidation as well as an initial characterization regarding drug–drug interaction and safety.

Methods

Different methods for generating sufficient amounts of the glucuronide were assessed and after purification structure elucidation of the glucuronide was performed via nuclear magnetic resonance spectroscopy (NMR). A series of in vitro experiments were conducted to determine its potential risk for drug–drug interaction. Confirmation of its identity was achieved by co-chromatography with hepatic incubations, which initially showed the presence of the metabolite.

Results

Chemical synthesis showed the most promising route for the formation of the proposed glucuronide and NMR determined the modification to be at the primary amino group attached to the pyrazolo-pyrimidine moiety. The retention time as well as the mass spectra in the co-chromatography aligned with the glucuronide of interest in the hepatocyte incubation, confirming the synthesized metabolite to be M1. Subsequent in vitro experiments showed that M1 did not inhibit any major CYP enzyme.

Conclusions

The tuvusertib metabolite M1 was identified as an N-glucuronide demonstrating no direct liabilities associated with drug–drug interactions (DDI) or safety implications. Furthermore, M1 can be used in bioanalyses as retention time marker or reference material in further clinical evaluations.